Skip to main content

Past Event
2 March 2017


  • Lisa M. Ferri
    T +1 212 506 2340
  • Christopher M. Mikson, MD
    T +1 202 263 3157
  • William R. Kucera
    T +1 312 701 7296
  • Henninger S. Bullock
    T +1 212 506 2528
  • Daniel L. Stein
    T +1 212 506 2646
  • Reb D. Wheeler
    T +1 212 506 2414

Symposium: Hot Topics in Life Sciences Law

Mayer Brown and the Center for Health & Pharmaceutical Law & Policy, Seton Hall University School of Law presented on March 2, 2017 a symposium exploring emerging issues and legal trends impacting the life sciences industry, including:

  • What’s Next for the FDA Under the New Administration and How Companies Can Prepare
  • The Future of Biosimilars: Regulatory, Legislative and Case Law Developments Impacting the Industry
  • Advertising by the Pharmaceutical Industry on Social Media: Pitfalls to Avoid
  • Navigating Conflicts and Ethical Considerations in Mergers & Acquisitions
  • Criminal Enforcement Trends in the Life Sciences Industry

The Honorable Michael Chagares, the United States Court of Appeals for the Third Circuit, gave a special keynote address. The program offered the opportunity for participants to network with in-house counsel, academics, members of the judiciary, and industry representatives. Additional speakers included:

Additional speakers included:

  • Gaia Bernstein, Michael J. Zimmer Professor of Law, Director, Seton Hall Institute for Privacy Protection, Co-Director, Gibbons Institute of Law Science and Technology, Seton Hall University School of Law
  • Tom DiLenge, President, Advocacy, Law & Public Policy Division, BIO
  • Howard Dorfman, ‎Distinguished Practitioner in Residence, Visiting Professor, Seton Hall University School of Law
  • Edward Hartnett, Richard J. Hughes Professor of Law, Seton Hall University School of Law
  • Stephen Lubben, Harvey Washington Wiley Chair, Corporate Governance & Business Ethics, Seton Hall University School of Law
  • Jeff Myers, ‎Vice President & Assistant General Counsel, Pfizer
  • Mark Rachlin, Senior Patent Counsel-Litigation, GlaxoSmithKline
  • Brian Walsh, Assistant General Counsel – IP, Bristol-Myers Squibb Company
  • Denelle Waynick, Vice President, Legal Affairs, UCB
  • Byron Webster, Director, Leerink Partners

Event Materials

The Future of FDA and Biosimilars

Mergers & Acquisitions: Ethical Considerations

Excerpts: Model Rules of Ethical Conduct

Media Coverage

Biosimilar Rules Likely To Survive ACA Battle, Lawyers Say

5 Social Media Pitfalls In The Pharmaceutical Industry

What Current Legal Developments Mean For Biosimilars

What Companies Can Expect From The New FDA

For a write-up of this event please visit Seton Hall's website.

Please visit

The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.